Latest News and Press Releases
Want to stay updated on the latest news?
-
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
-
Gyre's Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Liver Fibrosis Trial
-
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
-
Gyre Announces Publication of Protocol for Phase 3 Trial of F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
-
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
-
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
-
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
-
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference